We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has revised the Risk and Evaluation and Mitigation Strategy (REMS) for the generic anti-psychotic drug clozapine in an effort to improve patient monitoring for the rare blood disorder neutropenia.